Acetylon Pharmaceuticals, Inc.: Series B $12.4M

Posted in I - Series B, Q - 1Q11, R - NORTH EAST, X - HDAC, X - Oncology, XX - MA

Acetylon Pharmaceuticals (Cambridge, MA) a clinical-stage developer of selective deacetylase enzyme inhibitors focused on multiple myeloma, closed a $12.4M Series B financing. Participants include NewSpring Health Capital and others.

Syndax Pharmaceuticals, Inc.: Series A $9M

Posted in I - Series A, Q - 1Q10, R - NORTH EAST, X - HDAC, X - Oncology, XX - MA

Syndax Pharmaceuticals (Waltham, MA) a clinical-stage pharmaceutical company focused on an HDAC inhibitor for solid tumors and hematological tumors, closed a $9M Series A financing, bringing the total round to $49M. Participants include Domain Associates, MPM Capital, Avalon Ventures, Forward Ventures and Pappas Ventures.

Syndax Pharmaceuticals, Inc.: Series A $9M

Posted in I - Series A, Q - 1Q10, R - NORTH EAST, X - HDAC, X - Oncology, XX - MA

Syndax Pharmaceuticals (Waltham, MA) a clinical-stage pharmaceutical company focused on an HDAC inhibitor for solid tumors and hematological tumors, closed a $9M Series A financing, bringing the total round to $49M. Participants include Domain Associates, MPM Capital, Avalon Ventures, Forward Ventures and Pappas Ventures.

Acetylon Pharmaceuticals, Inc.: Series A $7.2M

Posted in I - Series A, Q - 3Q09, R - NORTH EAST, X - HDAC, X - Inflammation, X - Oncology, XX - MA

Acetylon Pharmaceuticals (Cambridge, MA) a development-stage small molecule company focused on Histone deacetylase inhibitors for oncology and inflammation indications, closed a $7.2M Series A financing. Participants may include Kraft Group Private Equity.

to top of page...